

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)



(10) International Publication Number
WO 2022/011262 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2021/041089

(22) International Filing Date:
09 July 2021 (09.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/050,742 10 July 2020 (10.07.2020) US
63/137,669 14 January 2021 (14.01.2021) US
63/185,699 07 May 2021 (07.05.2021) US

(71) Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) [FR/FR]; 101 Rue de Tolbiac, 75013 Paris (FR). UNIVERSITÉ D'AIX MARSEILLE [FR/FR]; 58 Boulevard Charles Livon, 13007 Marseille (FR). UNIVERSITÉ DE BORDEAUX [FR/FR]; 35 Place Pey Berland, 33000 Bordeaux (FR). REGENXBIO INC. [US/US]; 9804 Medical Center Drive, Rockville, MD 20850 (US). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3 rue Michel-ange, 75016 Paris (FR). CORLIEVE THERAPEUTICS [FR/FR]; 59 Rue de Ponthieu, 75008 Paris (FR).

(72) Inventors: CREPEL, Valérie; Bât B, 32 Chemin du Vallon de Toulouse, 13009 Marseille (FR). MULLE, Christophe; 24 Avenue de Chiquet, 33600 Pessac (FR). BOILEAU, Céline; Michelet De Lattre bat B3, 5 Boulevard Du Maréchal Koenig, 13009 Marseille (FR). DEFORGES, Séverine; 5 Rue des Ecoles, 33520 Bruges (FR). DANOS, Olivier; 9804 Medical Center Drive, Rockville, MD 20850 (US). MERCER, Andrew; 9804 Medical Center Drive, Rockville, MD 20850 (US). PORTER, Richard; 59 Rue de Ponthieu, 75008 Paris (FR). TEPE, April R.; 9804 Medical Center Drive, Rockville, MD 20850 (US).

(74) Agent: ARMSTRONG, Richard Todd; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND COMPOSITIONS FOR TREATING EPILEPSY

(57) Abstract: The present disclosure provides methods and compositions relating to gene therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting *Grik2* mRNA. In particular, the present disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuit.

WO 2022/011262 A1